The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC).
D. Jelovac
No relevant relationships to disclose
D. K. Armstrong
Consultant or Advisory Role - Abraxis BioScience; Amgen; Astellas Pharma; Boehringer Ingelheim; Celgene; Genentech; Genzyme; Morphotek; Oncogenex; VentiRx
Research Funding - Agensys; Astellas Pharma; Morphotek
S. Weil
Employment or Leadership Position - Morphotek
Other Remuneration - Morphotek
M. Phillips
Employment or Leadership Position - Morphotek
B. M. Schwartz
Research Funding - Morphotek
J. M. Estes
No relevant relationships to disclose
R. D. Alvarez
Research Funding - Morphotek